NIKKEI 225
37,623.86 -4.62 (-0.01%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
83.86 +0.29 (+0.35%) GOLD FUTURES
2,341.10 -1.40 (-0.06%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,349.38 -319.77 (-0.62%)
Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous close | 13.23 |
| Open | 13.15 |
| Bid | 13.08 x 1000 |
| Ask | 13.48 x 3200 |
| Day's range | 13.05 - 13.19 |
| 52-week range | 13.05 - 17.11 |
| Volume | |
| Avg. volume | 1,828,361 |
| Market cap | 41.412B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 36.31 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.64 (4.82%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | N/A |
- PR Newswire
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be
- PR Newswire
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, "SMBC") today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company. The new company will be dedicated to the incubation*1 of early drug discovery programs, primarily origin
- Business Wire
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
OSAKA, Japan & CAMBRIDGE, Mass., April 18, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) ENTYVIO.1 The subcutaneous administration of ENTYVIO was also approved by FDA in September 2023 for the maintenance treatment of adults with moderately to
